CancerDrs

Colorectal Cancer clinical trials

300 actively recruiting colorectal cancer trials in the United States. Cancer of the colon or rectum. Trials span screening, adjuvant therapy, and metastatic disease.

Data from ClinicalTrials.gov · last refreshed · Colorectal Cancer stats on SEER

62
Phase 1
105
Phase 2
14
Phase 3
2
Phase 4
117
Other

Colorectal Cancer by the numbers (U.S.)

154,270
Estimated new cases (2025)
52,900
Estimated deaths (2025)
65.4%
5-year relative survival
66
Median age at diagnosis

Source: NCI SEER Cancer Stat Facts

Browse colorectal cancer trials by state

Top trials by phase + site coverage

Phase 2, Phase 3 Recruiting Academic/Other

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

Sponsor: NRG Oncology
NCT ID: NCT05174169
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • Thomas Hospital — Fairhope, Alabama
  • Mobile Infirmary Medical Center — Mobile, Alabama

+ 1034 more sites in the U.S.

Phase 3 Recruiting Industry

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …

Sponsor: Pfizer
NCT ID: NCT07222800
Locations:
  • Ironwood Cancer & Research Centers — Chandler, Arizona
  • Ironwood Cancer & Research Centers — Gilbert, Arizona
  • Ironwood Cancer & Research Centers — Glendale, Arizona

+ 197 more sites in the U.S.

Phase 3 Recruiting Industry

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participa…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05253651
Locations:
  • Palo Verde Hematology Oncology — Glendale, Arizona
  • Mayo Clinic Building - Phoenix — Phoenix, Arizona
  • Mayo Clinic Hospital — Phoenix, Arizona

+ 129 more sites in the U.S.

Phase 3 Recruiting Industry

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxalipl…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06662786
Locations:
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
  • St. Bernard's Medical Center — Jonesboro, Arkansas
  • Highlands Oncology Group — Springdale, Arkansas

+ 78 more sites in the U.S.

Phase 3 Recruiting Industry

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fl…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06750094
Locations:
  • Ironwood Cancer and Research Center — Chandler, Arizona
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
  • Arizona Oncology Associates PC NAHOA — Prescott, Arizona

+ 68 more sites in the U.S.

Phase 3 Recruiting Industry

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instab…

Sponsor: GlaxoSmithKline
NCT ID: NCT05855200
Locations:
  • GSK Investigational Site — Tucson, Arizona
  • GSK Investigational Site — Los Angeles, California
  • GSK Investigational Site — New Haven, Connecticut

+ 46 more sites in the U.S.

Phase 3 Recruiting Industry

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compare eRapa to Placebo. The questions to b…

Sponsor: Rapamycin Holdings Inc.
NCT ID: NCT06950385
Locations:
  • City of Hope — Arcadia, California
  • Yale Cancer Center — New Haven, Connecticut
  • Georgetown University — Washington D.C., District of Columbia

+ 15 more sites in the U.S.

Phase 3 Recruiting Industry

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall surv…

Sponsor: EMD Serono Research & Development Institute, Inc.
NCT ID: NCT07549412
Locations:
  • Rocky Mountain Cancer Centers, LLP- Aurora — Lone Tree, Colorado
  • Florida Cancer Specialists-Broadway — Fort Myers, Florida
  • Florida Cancer Specialists - St. Petersburg Bayfront — St. Petersburg, Florida

+ 15 more sites in the U.S.

Phase 3 Recruiting Academic/Other

The Cancer of the Pancreas Screening-5 CAPS5)Study

Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.

Sponsor: Johns Hopkins University
NCT ID: NCT02000089
Locations:
  • Yale University — New Haven, Connecticut
  • Johns Hopkins Hospital — Baltimore, Maryland
  • Dana Farber Cancer Center, Harvard University — Boston, Massachusetts

+ 6 more sites in the U.S.

Phase 3 Recruiting Industry

Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer

The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer.

Sponsor: Surgimab
NCT ID: NCT03659448
Locations:
  • City of Hope National Medical Center — Duarte, California
  • Moores Cancer Center - UCSD Health — La Jolla, California
  • Cleveland Clinic Florida — Weston, Florida

+ 3 more sites in the U.S.

Phase 3 Recruiting Industry

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard…

Sponsor: AbbVie
NCT ID: NCT07525206
Locations:
  • Astera Cancer Care /ID# 279532 — East Brunswick, New Jersey
  • Northwell Health Center for Advanced Medicine. /ID# 279590 — Lake Success, New York
  • Compass Oncology - Rose Quarter /ID# 280127 — Portland, Oregon

+ 1 more site in the U.S.

Phase 3 Recruiting Academic/Other

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer. The names of the potential treatments involved in this study are: * Active surveillance …

Sponsor: Massachusetts General Hospital
NCT ID: NCT03803553
Locations:
  • Massachusetts General Hospital — Boston, Massachusetts
  • Memorial Sloan Kettering Cancer Center — New York, New York
  • Weill Cornell Medical College — New York, New York

Showing 12 of 300 trials. See all on ClinicalTrials.gov

Before you contact a trial site

Trial eligibility criteria are specific and strict. Reading them carefully before calling a site saves time. These guides walk through what to look for.

Medical disclaimer: Information on this page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-09-07